DOCKET NO.: ISPH-0596 PATENT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (Cancelled).

Claim 4 (Previously Presented): An antisense oligonucleotide 8 to 50 nucleobases in length that specifically hybridizes to nucleobases 1631 through 1769 of a nucleic acid molecule encoding human cholesteryl ester transfer protein (SEQ ID NO: 3), wherein said oligonucleotide comprises at least one modified internucleoside linkage and inhibits the expression of human cholesteryl ester transfer protein.

Claim 5 (Original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (Previously Presented): An antisense oligonucleotide 8 to 50 nucleobases in length that specifically hybridizes to nucleobases 1631 through 1769 of a nucleic acid molecule encoding human cholesteryl ester transfer protein (SEQ ID NO: 3), wherein said oligonucleotide comprises at least one modified sugar moiety and inhibits the expression of human cholesteryl ester transfer protein.

Claim 7(Original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8(Previously Presented): An antisense oligonucleotide 8 to 50 nucleobases in length that specifically hybridizes to nucleobases 1631 through 1769 of a nucleic acid molecule encoding human cholesteryl ester transfer protein (SEQ ID NO: 3), wherein said oligonucleotide comprises at least one modified nucleobase and inhibits the expression of human cholesteryl ester transfer protein.

Claim 9(Original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10(Previously Presented): An antisense oligonucleotide 8 to 50 nucleobases in length that specifically hybridizes to nucleobases 1631 through 1769 of a nucleic acid molecule encoding human cholesteryl ester transfer protein (SEQ ID NO: 3), wherein said oligonucleotide is a chimeric oligonucleotide and inhibits the expression of human cholesteryl ester transfer protein.

11(Cancelled).

12(Previously Presented): A composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier or diluent.

13(Original): The composition of claim 12 further comprising a colloidal dispersion system.

14 (Cancelled).

15 (Previously Presented). A method of inhibiting the expression of human cholesteryl ester transfer protein in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 4 so that expression of human cholesteryl ester transfer protein is inhibited.

Claims 16-20 (Cancelled).

21 (Previously Presented): A composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier or diluent.

22 (Previously Presented): The composition of claim 21 further comprising a colloidal dispersion system.

23 (Previously Presented): A method of inhibiting the expression of human cholesteryl ester transfer protein in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 6, so that expression of human cholesteryl ester transfer protein is inhibited.

24 (Previously Presented): A composition comprising the compound of claim 8 and a pharmaceutically acceptable carrier or diluent.

25(Previously Presented): The composition of claim 21 further comprising a colloidal dispersion system.

26(Previously Presented): A method of inhibiting the expression of human cholesteryl ester transfer protein in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 8, so that expression of human cholesteryl ester transfer protein is inhibited.

27(Previously Presented): A composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier or diluent.

28(Previously Presented): The composition of claim 27 further comprising a colloidal dispersion system.

29(Previously Presented): A method of inhibiting the expression of human cholesteryl ester transfer protein in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 10, so that expression of human cholesteryl ester transfer protein is inhibited.